All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Aspacytarabine granted orphan drug designation by the FDA

Aug 8, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in MDS.

On August 1, 2022, aspacytarabine, an investigational novel antimetabolite, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with myelodysplastic syndromes (MDS).1

Aspacytarabine (BST-236) is a novel proprietary antimetabolite. It is made up of cytarabine covalently bound to asparagine. Aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine and relative sparing of normal tissues, making it a suitable therapy for older adults who are unfit for intensive therapy. The FDA previously granted aspacytarabine orphan drug designation for the treatment of patients with acute myeloid leukemia (AML) in 2019.1

The safety and efficacy of aspacytarabine as a single-agent first-line therapy for patients with AML have previously been demonstrated, and additional studies are ongoing to assess aspacytarabine as a second-line treatment for patients with relapsed/refractory MDS. The AML Hub has previously published an article and an expert opinion on aspacytarabine.

  1. Cision PR Newswire. Biosight granted orphan drug designation from the FDA for aspacytarabine for the treatment of myelodysplastic syndromes. https://www.prnewswire.com/il/news-releases/biosight-granted-orphan-drug-designation-from-the-fda-for-aspacytarabine-for-the-treatment-of-myelodysplastic-syndromes-301596832.html. Published Aug 1, 2022. Accessed Aug 4, 2022.